Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w...
8 transactions — including 0 buys declared by Iovance Biotherapeutics, Inc. executives to SEC / AMF / BaFin.
17 institutional funds report a position on IOVA in their latest SEC quarterly filing.
15 recent articles on IOVA.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Automatic detection when 3+ executives buy the same stock simultaneously — historically the most reliable signal.
Berkshire (Buffett), Pershing Square (Ackman), Tiger Global, Bridgewater + 200 more. Who buys what, each quarter.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot small caps whose retail interest explodes before the rest of the market. 100+ tickers monitored.
Create your watchlist and receive every morning at 8am the Brief of events on YOUR tickers.
This public page only shows a preview. The full analysis of IOVA on the Kairos Insider dashboard includes:
Free signup · Premium €29/month no commitment